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Summary
 
OBJECTIVE
 
 
 
To assess whether there is a relationship
between the effectiveness of alendronate treatment in
postmenopausal women with osteoporosis and BsmI
vitamin D receptor (VDR) genotypes.
 
DESIGN
 
 
 
Prospective baseline-controlled clinical trial.
 
PATIENTS
 
 
 
Sixty-eight Italian osteoporotic women
were enrolled and treated with alendronate at a dose
of 10 mg/day for 12 months.
 
MEASUREMENTS
 
 
 
At entry and after treatment, lumbar
bone mineral density (BMD) and serum osteocalcin
(OC) and urinary deoxypyridinoline/creatinine ratio
(DPD-Cr) levels were evaluated. DNA was extracted
from blood and analysed for the BsmI polymorphism
of the VDR gene.
 
RESULTS
 
 
 
The mean percentage (% 
 
– –
––
 
 SD) change from
baseline in lumbar BMD was significantly higher
(
 
P
 
 < 0·01) in bb than in BB BsmI VDR genotypes
(7·92 
 
– –
––
 
 4·31 
 
vs.
 
 3·40 
 
– –
––
 
 1·81). No significant difference in
lumbar BMD was observed in Bb VDR patients
(6·01 
 
– –
––
 
 3·89) in comparison with other groups. The
mean percentage of change in serum OC and urinary
DPD-Cr levels was significantly (
 
P
 
 < 0·01) lower in
individuals with bb than in those with BB BsmI
VDR genotypes (
 
- -
--
 
14·34 
 
– –
––
 
 2·87 
 
vs.
 
 
 
- -
--
 
10·39 
 
– –
––
 
 1·43 and
 
- -
--
 
9·61 
 
– –
––
 
 5·56 
 
vs.
 
 
 
- -
--
 
4·61 
 
– –
––
 
 2·31). No significant difference
in serum OC and urinary DPD-Cr levels was observed
in Bb VDR patients (
 
- -
--
 
12·31 
 
– –
––
 
 2·11 and 
 
- -
--
 
6·52 
 
– –
––
 
 2·65) in
comparison with other groups.
 
CONCLUSION
 
 
 
The different BsmI vitamin D receptor
genotypes modify the pharmacological response to
alendronate treatment in postmenopausal women with
osteoporosis.
 
Osteoporosis is a multifactorial disease characterized by a low
bone mineral density (BMD). Several hormonal and environ-
mental factors affect the risk of osteoporosis, and many genetic
factors may strongly influence the sensitivity of the bone to these
(Eisman, 1999). In fact, up to 85% of the variance in BMD is
genetically determined and various candidate genes have been
proposed to be involved in this process (Eisman, 1999). In par-
ticular, it has been shown that alleles at the vitamin D receptor
(VDR) gene are associated with bone density (Morrison 
 
et al
 
.,
1994) and that the VDR gene is associated with a particular bone
density pattern that varies with chronological age, sex and ana-
tomical site (Gong 
 
et al
 
., 1999). The VDR gene polymorphism
is also related to a higher prevalence in vertebral fractures
(Gomez 
 
et al
 
., 1999; Uitterlinden 
 
et al
 
., 2001), probably acting
independently of BMD (Uitterlinden 
 
et al
 
., 2001).
Many therapeutic options are currently available for the pre-
vention and treatment of postmenopausal osteoporosis (Altkorn
& Vokes, 2001). Furthermore, few data are available in the liter-
ature regarding genetic factors that could influence the clinical
response to antiosteoporotic treatments (Keen & Kelly, 1997).
Recent studies suggest that VDR gene polymorphisms may
modify the BMD response to calcium (Ca) intake (Dawson-
Hughes 
 
et al
 
., 1995; Ferrari 
 
et al
 
., 1995; Kiel 
 
et al
 
., 1997), Ca
and vitamin D supplementation (Graafmans 
 
et al
 
., 1997; Howard
 
et al
 
., 1995; Wishart 
 
et al
 
., 1997), cyclic etidronate administra-
tion (Marc 
 
et al
 
., 1999) and hormone replacement therapy (HRT)
(Deng 
 
et al
 
., 1998; Kurabayashi 
 
et al
 
., 1999). Thus, VDR gene
polymorphisms might be important in predicting the effective-
ness of an antiosteoporotic treatment.
Today, administration of alendronate at a standard dose of
10 mg daily is the ‘gold standard’ for the treatment of postmen-
opausal osteoporosis (Altkorn & Vokes, 2001), but no data are
available in the literature about different BMD responses to this
drug and VDR gene polymorphisms.
The aim of the present study was to test whether a relationship
exists between a VDR gene polymorphism and the effectiveness
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of alendronate treatment in postmenopausal women with
osteoporosis.
 
Patients and methods
 
The procedures used during the study were in accordance with
the guidelines of the Helsinki Declaration on human experimen-
tation. The protocol was approved by the local ethics committee
of the University of Naples.
Before entering the study, the purpose of the protocol was
explained to all women attending the Departments of Gynae-
cology of the Universities of Catanzaro and Naples. Written
informed consent was obtained by all subjects.
 
Patients
 
Between January and August 2000, 68 ambulatory postmeno-
pausal women (FSH > 40 IU/ l, 17
 
b
 
-oestradiol (E2) < 20 pmol/ l)
with osteoporosis were enrolled in the study protocol.
Inclusion criteria were: natural postmenopause, and BMD
values of at least 2·5 standard deviations (SD) below the mean bone
density of the peak value for sex-matched healthy young adults
(
 
-
 
2·5 T-score) at posterior–anterior lumbar spine. All women
enrolled were genetically unrelated.
Exclusion criteria were: active rheumatoid arthritis; gastro-
intestinal or liver disease; metabolic, neoplastic or endocrine
diseases; history of acute or recurrent vascular thrombosis;
secondary causes of osteoporosis, such as hyperparathyroidism,
Paget’s disease of bone, or renal osteodystrophy; previous
treatment with bisphosphonates, sodium fluoride, calcitonin,
oestroprogestins, anabolic steroids, corticosteroids, Ca, vitamin D,
or phosphate (P); treatment with corticosteroids, thiazide diuretics
or other drugs interfering with bone metabolism; serum creati-
nine (Cr) > 133 
 
m
 
mol/ l, history of gastrointestinal side-effects;
body mass index (BMI) < 18 kg/m
 
2
 
 or > 30 kg/m
 
2
 
. Women with
plasma 25-OH-vitamin D levels lower than 25 nmol/ l or abnor-
mal serum Ca (normal values 2·2–2·6 mmol/ l), P (normal values
1·0–1·4 mmol/ l) and PTH (normal values 10–65 ng/ l) concen-
trations were excluded from the study.
Also excluded were women who regularly used any medica-
tion that had the potential to cause gastrointestinal irritation, or
who used drugs to inhibit gastric acid secretion, women who
smoked more than 20 cigarettes per day, or who drank more than
three alcoholic beverages per day.
 
Treatment and study protocol
 
All subjects received alendronate (Fosamax, Merck Sharp & Dhome,
Rome, Italy) at a dose of 10 mg/day. Patients were instructed to
take the medication orally in the morning at least 30 min before
breakfast with abundant water and on an empty stomach after
an overnight fast, and to remain upright for at least 30 min after
dosing. The duration of the treatment was 12 months.
At baseline and after treatment, BMD and bone metabolism
were measured in all groups as detailed below. Both patients and
clinicians were blind with respect to these results throughout the
study period.
At baseline and every 3 months of treatment, Ca intake,
alcohol consumption and physical activity were evaluated as
described previously (Palomba 
 
et al
 
., 1999, 2002). Ca intake and
alcohol consumption were assessed by a dietary history of
patients using a semiquantitative diet questionnaire developed by
dieticians of the University of Naples. Ca intake was expressed
as a score ranging from 1 to 3, according to the following scale:
score 1 for a Ca intake < 500 mg/day, score 2 for a Ca intake of
500–1000 mg/day, and score 3 for a Ca intake > 1000 mg/day.
Alcohol consumption was also expressed as a score ranging from
1 to 3, according to the following scale: score 1 for an alcohol
consumption of < 1000 mg/day, score 2 for an alcohol consump-
tion of 1000–2000 mg/day, and score 3 for an alcohol consump-
tion of > 2000 mg/day. A semiquantitative questionnaire was also
used to evaluate the patients’ daily physical activity. Physical
activity was expressed as a score ranging from 1 to 3, according
to the following scale: score 3 (high physical activity) was
assigned to women who exercised regularly; score 2 (moderate
physical activity) was assigned to women who did not exercise
regularly but participated daily in activities such as cleaning the
house, climbing stairs, or walking to work, to the bus stop, or to
a restaurant; score 1 (low physical activity) was assigned to women
who did not participate in any of above-mentioned activities.
No dietary restrictions or changes were implemented during
the study. To ensure adequate Ca intake, all patients with a Ca
intake of less than 1000 mg received daily supplements of
elemental Ca in the form of an effervescent tablet composed of
Ca carbonate (500 mg/day; Cacit, Procter & Gamble, Rome,
Italy) to achieve a total daily Ca intake of at least 1000 mg. This
supplement was taken at lunch.
 
BMD measurement
 
The BMD was determined by dual energy X-ray absorptiometry
(Hologic QDR 1000, Waltham, MA, USA) at posterior–anterior
lumbar spine (vertebrae L2 to L4).
The precision of the measurements expressed as coefficient of
variation (CV) 
 
in vitro
 
 for repeated BMD determinations for two
standard phantom in our laboratory was 0·41% and 0·43% for
the Universities of Naples and Catanzaro, respectively. The CV
 
in vivo
 
 was evaluated comparing two measurements performed
at 7-day intervals in 40 volunteers and was 1·0% and 1·2% for
the Universities of Naples and Catanzaro, respectively.
The absorptiometries were examined by the same observer
blind with respect to different VDR genotypes.
 Alendronate treatment and VDR genotypes
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We used the mean of three scans to calculate bone mineral con-
tent (BMC). The BMD values were calculated by the software
of the bone densitometer dividing the BMC (g/cm) for the bone
width (cm) and expressed directly as an index (g/cm
 
2
 
).
Vertebral fractures were assessed from thoracic and lumbar
(T4–L4) lateral and anterior–posterior spinal radiographs taken
at baseline and from lateral spinal radiographs taken at the end
of the study. Potential fractures were identified by quantitative
morphometry according to the guidelines of the US National
Osteoporotic Foundation Working Group on Vertebral Fractures
(Kiel, 1995), and subsequent visual verification of incident
fractures was performed by a qualified radiologist.
 
Biochemical assays
 
At entry serum FSH and E
 
2
 
 levels were assayed in all women to
confirm the postmenopausal status. At entry and after treatment,
Ca, P, PTH, osteocalcin (OC) and urinary creatinine (Cr) and
deoxypyridinoline (DPD) levels were determined using com-
mercial kits (Palomba 
 
et al
 
., 2002).
In particular, serum OC levels and urinary Cr-corrected free
DPD were used as markers of bone formation and of bone
resorption, respectively. Serum OC levels (reference range 0·53–
2·34 nmol/ l) were assayed by an immunoradiometric assay
(IRMA) (Diagnostic Products Corporation, Los Angeles, CA,
USA) with a sensitivity of 0·02 nmol/ l, and intra- and interassay
CVs of 4·5% and 3·5%, respectively. Urinary DPD concentra-
tions (reference range normalized for Cr levels 3·0–7·4 nmol/
mmol) were assayed by an enzyme immunoassay (EIA) (Metra
Biosystems, Milan, Italy) with a sensitivity of 1·1 nmol/ l, and
intra- and interassay CVs of 7·6% and 5·5%, respectively. Uri-
nary concentrations of Cr (reference range 8·8–14·1 mmol/24 h)
were measured with the use of an autoanalyser (Monarch 1000,
Instrumentation Laboratory, Milan, Italy). Cr-corrected values
were calculated by dividing DPD by urinary Cr measured using
a standard colorimetric assay (DPD-Cr).
Blood and 24-h urine samples were collected after an over-
night fast between 0830 and 0930 h to avoid the interference of
circadian changes. The urine samples were taken using tubes
covered with light-resistant paper. Patients were asked to refrain
from eating foods containing fat or gelatine within 12 h of their
clinic visit. Serum samples were separated within 1 h from
collection and kept frozen at 
 
-
 
80 
 
°
 
C, and urine was stored at 
 
-
 
20 
 
°
 
C
until biochemical analysis. All samples from the same woman
were analysed in the same assay and were analysed blind by a
central laboratory (University of Catanzaro).
 
DNA analysis
 
The DNA analysis was performed in the Department of Clinical
and Experimental Medicine of the University of Naples.
At entry, DNA was extracted from whole-blood samples with
the salting-out procedure described by Miller 
 
et al.
 
 (1988).
Genotypic analysis of VDR gene polymorphisms was determined
by polymerase chain reaction (PCR) amplification and enzymatic
digestion of the products with BsmI restriction enzyme. The for-
ward and reverse primers were modified from Sainz 
 
et al
 
. (1997).
PCR was performed with a Techne Progene Thermal Cycler
(Cambridge, UK) under standard conditions for 30 cycles and at
65 
 
°
 
C annealing temperature.
DNA was digested with BsmI under standard conditions and
the products were analysed by electrophoresis on a 1·5% agarose
gel containing ethidium bromide.
The alleles were defined as ‘B’ or ‘b’ in the absence or in the
presence of the restriction site, respectively.
 
Safety evaluation
 
Standard clinical evaluations and laboratory analyses, including
haematological, renal function and liver function tests, and micro-
scopical examinations of sediment from midstream urine speci-
mens were performed before treatment and after every 6 months.
A mammography was performed before treatment and then yearly.
The subjects were instructed to report the appearance of
adverse experiences (AEs) in a daily diary.
 
Statistical analysis
 
The analysis of variance (
 
ANOVA
 
) followed by the Newman–
Keuls multiple range test was used to compare multiple measures
of age, time since menopause, body mass index (BMI), BMD
and biochemical data. Wilcoxon’s signed rank-test was used to
compare parity, cigarettes smoked, alcohol consumption, Ca
intake and physical activity. The proportion of women receiving
Ca supplements in the three groups of polymorphism was com-
pared using the 
 
c
 
2
 
-test. Fisher’s exact test was used to compare
the incidence of AEs between treatment groups. The statistical
analysis was performed using SPSS 9·0 (SPSS Inc., Chicago, IL,
USA).
The statistical significance was set at 
 
P
 
 < 0·01. Data were nor-
mally distributed and were expressed as mean 
 
–
 
 SD.
 
Results
 
Sixty-four of 68 enrolled osteoporotic postmenopausal women
were analysed.
No drop-out was due to drug-related AEs. Three women (one
from each VDR genotype group) dropped out from the study
because they stopped treatment during the third month of the
alendronate period for personal reasons. In addition, one other
woman (in the bb VDR group) dropped out because she experi-
enced an AE consisting of surgical intervention for gall stones.
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After alendronate treatment, we observed a significant
(
 
P
 
 < 0·01) increase in lumbar spine BMD (0·577 
 
–
 
 0·074 
 
vs.
 
0·613 
 
–
 
 0·079 mg/cm
 
2
 
, before and after treatment, respectively)
in our sample studied. The change in BMD (mean 
 
–
 
 SD) from
baseline was 6·39 
 
–
 
 4·12%. Serum OC (1·12 
 
–
 
 0·03 nmol/ l) and
urinary DPD-Cr levels (6·11 
 
–
 
 0·12 nmol/mmol) were sig-
nificantly (
 
P
 
 < 0·01) lower in comparison to basal values
(1·18 
 
–
 
 0·03 and 6·54 
 
–
 
 0·14 for OC and DPD-Cr, respectively).
The changes in serum OC and urinary DPD-Cr levels
(mean 
 
–
 
 SD) from baseline were 12·7 
 
–
 
 1·1% and 7·6 
 
–
 
 0·9%,
respectively.
The VDR genotype prevalence in the study population is
shown in Table 1. In our population study, the BsmI VDR
genotype frequencies were in Hardy–Weinberg equilibrium (Ott,
1999). Considering the different BsmI VDR genotypes, no sig-
nificant differences in baseline data were detected between the
three groups of women (Table 1).
At entry, there was also no significant difference between VDR
genotype groups with respect to lumbar BMD, and serum OC
and urinary DPD-Cr levels (Table 2). After alendronate treat-
ment, a significant (
 
P
 
 < 0·01) difference in lumbar BMD, and in
serum OC and urinary DPD-Cr levels was observed in each
group of VDR genotype in comparison with baseline values.
Furthermore, no statistically significant difference was detected
between the three groups of BsmI VDR genotypes (Table 2).
The mean percentage change (% 
 
–
 
 SD) of lumbar BMD was
significantly higher in patients homozygous for bb in comparison
with those homozygous for BB genotypes (7·92 
 
–
 
 4·31 
 
vs.
 
3·40 
 
–
 
 1·81; 
 
P
 
 < 0·01). No significant difference in lumbar BMD
change (6·01 
 
–
 
 3·89) was observed in patients heterozygous for
Bb in comparison with those homozygous for BB and bb.
The mean percentage change in serum OC levels was signific-
antly lower in patients with bb compared to those with BB genotypes
(
 
-
 
14·34 
 
–
 
 2·87 
 
vs.
 
 
 
-
 
10·39 
 
–
 
 1·43; 
 
P
 
 < 0·01), whereas no signif-
icant difference was observed in those heterozygous for Bb VDR
patients (
 
-
 
12·31 
 
–
 
 2·11) in comparison with other homozygous
groups. The mean percentage change in urinary DPD-Cr levels
was significantly lower in those homozygous for bb than in those
homozygous for BB BsmI VDR genotypes (
 
-
 
9·61 
 
–
 
 5·56 
 
vs.
 
-
 
4·61 
 
–  2·31; P < 0·01) whereas no significant difference was
observed in patients heterozygous for Bb VDR genotypes
(- 6·52 –  2·65) in comparison with other homozygous groups.
Figure 1 shows the individual percentage change in lumbar
BMD and in serum OC and urinary DPD-Cr levels in each
woman according to BsmI VDR genotypes after 12 months of
alendronate administration.
  
VDR genotypes 
BB Bb bb
No. (%) 12 (18·75) 23 (35·93) 29 (45·31)
Age (years) 64·33 –  4·42 65·39 –  3·33 64·59 –  6·90
BMI (kg/m2) 25·16 –  1·65 25·59 –  1·31 25·26 –  2·02
Time since menopause (years) 14·42 –  4·17 14·91 –  3·68 14·34 –  2·88
FSH (IU/l) 62·9 –  13·4 68·0 –  11·7 65·3 –  11·9
E2 (pmol/ l) 17·2 –  1·9 16·1 –  1·7 17·4 –  1·3
Parity (number) 2·0 –  0·4 2·1 –  0·4 1·8 –  0·3
Smoking history
Never smoked (%) 6 (50·0) 13 (56·5) 15 (51·7)
Past smoker (%) 2 (16·7) 4 (17·4) 5 (17·2)
Current smoker (%) 4 (33·3) 6 (26·1) 9 (31·1)
Cigarettes smoked (number/day) 5·2 –  3·1 5·6 –  3·8 4·7 –  3·5
25-OH-vitamin D (nmol/l) 65·1 –  13·9 72·2 –  15·1 69·7 –  14·6
Ca (mmol/ l) 2·44 –  0·19 2·42 –  0·13 2·39 –  0·16
P (mmol/ l) 1·21 –  0·22 1·14 –  0·15 1·19 –  0·18
PTH (ng/ l) 45·6 –  13·5 43·9 –  11·1 46·2 –  15·7
Ca intake score* 1·8 –  0·8 1·7 –  0·8 1·7 –  0·8
Women taking Ca supplementation (%) 9 (75·0) 18 (78·3) 23 (79·3)
Alcohol intake score† 1·2 –  0·5 1·3 –  0·6 1·4 –  0·5
Physical activity score‡ 1·3 –  0·7 1·3 –  0·6 1·4 –  0·7
Lumbar spine T-score - 3·33 –  0·60 - 3·35 –  0·81 - 3·47 –  1·14
Values are expressed as mean – standard deviation (SD); BMI, body mass index; E2, oestradiol.
*1 = < 500 mg/day, 2 = 500–1000 mg/day, 3 = > 1000 mg/day; †1 = < 1000 mg/day, 
2 = 1000–2000 mg/day, 3 = > 2000 mg/day; ‡1 = low, 2 = moderate, 3 = high.
Table 1 Baseline characteristics of the subjects 
according to the VDR gene BsmI polymorphism
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Discussion
Alendronate is a potent and specific inhibitor of osteoclast-mediated
bone resorption. Its administration prevents postmenopausal
bone loss in women without osteoporosis and it is an effective
treatment for osteoporotic women. A significant reduction in the
incidence of vertebral and nonvertebral fractures in postmeno-
pausal osteoporotic women with or without pre-existing fractures
  
VDR genotypes 
BB Bb bb
BMD lumbar spine (g/cm2)
Baseline 0·582 –  0·081 0·579 –  0·077 0·573 –  0·071
After treatment 0·602 –  0·085* 0·613 –  0·081* 0·618 –  0·076*
Osteocalcin (nmol/ l)
Baseline 1·18 –  0·10 1·17 –  0·12 1·18 –  0·12
After treatment 1·05 –  0·09* 1·03 –  0·10* 1·01 –  0·12*
DPD/Cr ratio (nmol/mmol)
Baseline 6·71 –  0·46 6·68 –  0·55 6·64 –  0·59
After treatment 6·40 –  0·53* 6·23 –  0·53* 6·01 –  0·66*
Values are expressed as mean –  standard deviation (SD); DPD/Cr, deoxypyridinoline/creatinine 
ratio; *P < 0·01 vs. baseline.
Table 2 Bone mineral density (BMD) and 
biochemical markers before and after 12 months of 
alendronate treatment (10 mg/day) according to 
the VDR gene BsmI polymorphism
Fig. 1 Percentage change in lumbar BMD and in 
serum OC and urinary DPD-Cr levels in each 
patient classified according to the BsmI VDR 
genotypes. A significant difference (P = 0·004, 
P = 0·001 and P = 0·002 for lumbar BMD, serum 
OC and urinary DPD-Cr levels, respectively) was 
observed between patients homozygous for bb and 
those homozygous for BB BsmI VDR genotypes.
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has been demonstrated with the use of alendronate (Jeal et al.,
1997; Altkorn & Vokes, 2001; Sharpe et al., 2001).
Prolonged and continuous treatment with alendronate at low
doses has also been shown to be effective in preventing post-
menopausal and glucocorticoid-induced bone loss (Sharpe et al.,
2001). Indeed, in postmenopausal osteoporotic women the addition
of 5 mg alendronate to HRT induced a greater increase in BMD than
HRT alone but not significantly different in comparison with the
addition of a standard dose of 10 mg daily (Palomba et al., 2002).
According to previous studies, our results confirm that
12 months of continuous oral alendronate 10 mg/day induces a
significant increase in BMD lumbar spine in postmenopausal
women with osteoporosis (Jeal et al., 1997; Sharpe et al., 2001;
Palomba et al., 2002). Furthermore, the aim of our study was to
test the association between the alendronate-induced bone gain
with VDR genotypes. Indeed, the lumbar spine increases in BMD
are significantly greater in women homozygous for bb compared
to those homozygous for BB. Serum and urinary levels of bone
turnover markers also decreased significantly more in bb than in
BB subjects. Heterozygous Bb VDR patients showed an inter-
mediate percentage change in lumbar BMD, serum OC and
urinary DPD-Cr levels that was not significantly different from
that seen in those homozygous for BB and bb.
In our study, the BsmI VDR genotypes frequencies were in
Hardy–Weinberg equilibrium (Ott, 1999) and the BsmI VDR
allelic frequencies in the study population were comparable to
published data in European postmenopausal and osteoporotic
unrelated women (Vandevyver et al., 1997).
Our data are a further confirmation that bone metabolism is
largely controlled by genetic mechanisms, and that bone loss and
gain are also genetically determined with respect to antio-
steoporotic treatments. In particular, the significant difference in
lumbar spine BMD change observed, after treatment, between
homozygous bb and BB VDR subjects supports the initial
hypothesis that different BsmI VDR genotypes modify the
pharmacological response to alendronate treatment in osteoporotic
women.
To obtain results with minimal confounding factors we
enrolled women with no significant differences in demographic
characteristics, and with a similar Ca dietary intake of at least
1000 mg daily and with serum 25-OH-vitamin D levels higher
than 25 nmol/ l (Dawson-Hughes et al., 1995; Ferrari et al.,
1995; Graafmans et al., 1997; Howard et al., 1995).
At present, there is no explanation of the relationship between
alendronate action and VDR polymorphisms, and the mechanism
by which the different VDR genotypes may account for changes
in the bone gain after alendronate administration is unknown. It
has been demonstrated that alendronate impairs bone resorption
induced by 1,25(OH)2D3 and retinoids, and that it inhibits the
1,25(OH)2D3/VDR-induced production of osteocalcin (Fleisch,
1998; Rogers et al., 2000).
In a recent paper (Kurabayashi et al., 1999), the VDR and
oestrogen receptor gene polymorphisms were related to the effec-
tiveness of HRT on bone density in Japanese women. In this ret-
rospective study (Kurabayashi et al., 1999), it was shown that
subjects with genotype bb (TT in Japanese women) exhibit a sig-
nificantly greater increase in BMD than those with Bb genotype
after 2 years of HRT. Furthermore, only one woman was
homozygous BB and was not included in the results. Indeed, the
population studied was very heterogeneous and unselected with
regard to dietary, BMD and progestin balance.
Our results are partially in contrast with those published by
Marc et al. (1999). In that study, a higher response to etidronate
treatment was observed in BB in comparison with bb VDR
genotypes (Marc et al., 1999). There are various possible reasons to
explain this discrepancy in the results. First, the Ca supplemen-
tation was administered to each woman without a clear evaluation
of the daily Ca intake. In addition, no selection was performed
according to the plasma vitamin D levels. Furthermore, we can-
not exclude the different pharmacological properties between
alendronate and etidronate (Russel & Rogers, 1999).
In conclusion, our study demonstrates that a vitamin D recep-
tor gene polymorphism plays a role in the pharmacological
response to alendronate treatment and confirms that knowledge
of the genetic background could improve the selection of optimal
antiosteoporotic treatment. Further studies are necessary to
clarify the possible role of the allelic variants of the vitamin D recep-
tor and of other genes in the modulation of the pharmacological
response to antiosteoporotic treatment.
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